Outgrowth of solid tumors requires blood supply to the tumor. Tumor angiogenesis is dependent on the interplay between tumor-derived angiogenic factors and stromal cells. Recently, it has been shown that the neurotransmitter dopamine is a potent inhibitor of VEGF-induced angiogenesis. Moreover, there is evidence that patients with schizophrenia have a hyperreactive dopaminergic system and are relatively protected from cancer.
C
ancer progression is a complex process that is dependent on the growth rate of tumor cells, tumor vascularization, and metastatic potential of tumor cells. Genetic characteristics of the tumor itself, including expression of specific oncogenes, can predict the malignant potential of the tumor (1, 2) .
Successful outgrowth of tumor cells requires vascularization of the tumor (3) (4) (5) . In vivo angiogenesis is tightly regulated by pro-and antiangiogenic factors. The induction of novel blood vessel sprouts from existing vessels is thought to result from tipping the angiogenic balance toward the proangiogenic side (6) (7) (8) (9) . Most malignant tumors produce VEGF as the primary factor to induce angiogenesis, and there is evidence that the level of VEGF expression by tumor cells can predict outcome in some types of cancer (10, 11) . However, the angiogenic response is not only determined by tumor-derived growth factors, but also by pro-and antiangiogenic factors produced by host stromal cells and the response of host endothelial cells to antiangiogenic and angiogenic factors (12) (13) (14) .
We are interested in the contribution of host characteristics to tumor angiogenesis and tumor growth. There is evidence that some individuals are relatively protected from the development of cancer. For example, it has been reported that patients with schizophrenia who have a hyperreactive dopaminergic system (15-17) have a reduced incidence of malignancies, despite increased smoking and drinking habits in this population (18) (19) (20) . Interestingly, a recent study has shown that the neurotransmitter dopamine is a potent inhibitor of VEGF-induced angiogenesis (21) . Dopamine exerts its antiangiogenic effect via binding to D2-receptors on endothelial cells, a process that induces internalization of the VEGF receptor-2, which prevents activation of angiogenesis (21) . Moreover, dopamine or dopamine receptor agonists can inhibit the growth of malignant tumors in mice (22, 23) . In view of these findings, it is likely that the dopaminergic system is an important host factor for determining the final outcome of the angiogenic response and tumor growth.
To test the hypothesis that individual differences in reactivity of the dopaminergic system are coupled to individual differences in tumor growth and angiogensis, we used apomorphinesusceptible (APO-SUS) Wistar rats and their mirror image, namely apomorphine-unsusceptible (APO-UNSUS) Wistar rats as a model in this study. These two types of rat are present in unselected outbred populations of Wistar rats and display a bimodal variation in the response to the dopaminergic agonist apomorphine, the selection criterion for breeding the APO-SUS and APO-UNSUS lines of rats (24, 25) .
APO-SUS rats share several characteristics with patients who suffer from schizophrenia. Behaviorally, the reduced prepulse inhibition and latent inhibition observed in APO-SUS rats is reminiscent of similar characteristics in schizophrenia patients (26) (27) (28) . Like patients with schizophrenia, APO-SUS rats are marked by an enhanced sensitivity to dopaminergic drugs such as amphetamine and apomorphine (24, 25, (29) (30) (31) . Furthermore APO-SUS rats and schizophrenic patients show a hyperreactive hypothalamus-pituitary-adrenal axis (32, 33) . Most important, however, both APO-SUS rats and patients with schizophrenia are characterized by an increased expression of tyrosine hydroxylase mRNA and an increased number of dopamine D2 receptors in the brain (34, 35) . In fact, APO-SUS rats are characterized by a hyperreactive dopaminergic system.
In this study, we addressed the question of whether the hyperreactive dopaminergic system in APO-SUS rats results in reduced tumor growth and angiogenesis. Therefore, we examined tumor growth and angiogenesis in matrigel implants containing mammary adenocarcinoma cells (MADB106) (36) . In addition, we determined experimental lung metastasis formation after i.v. administration of MADB106 cells in APO-SUS and APO-UNSUS rats.
MATERIALS AND METHODS

Animals
Male APO-SUS and APO-UNSUS rats aged 8-10 wks were used in all experiments. The selection procedure has been described in detail by Cools et al. (24) . In brief, 60 male and 60 female rats of an outbred Wistar population were given s.c. injections of 1.5 mg/kg apomorphine, which induces stereotyped gnawing behavior. The gnawing score was determined automatically, and breeding of the APO-SUS line was started with nine pairs of rats with a gnawing score in the upper quartile. Breeding of APO-UNSUS rats was started with nine pairs of rats with gnawing scores in the lower quartile. Throughout the breeding procedure, retention of the response to apomorphine was tested in rats of the first litter of a generation.
MADB106 cells
MADB106 cells were maintained as an adherent monolayer in culture in RPMI-1640 supplemented with L-glutamine (2 mM), penicilin, and streptomycin as antibiotics; 10% fetal calf serum (heat inactivated, Gibco, Grand Island, NY); 1 µM sodiumpyruvate; and 1 mM nonessential amino acids.
Matrigel implants
For in vivo monitoring of tumor-associated angiogenesis, we adapted the s.c. matrigel implant model previously described by Passaniti et al. (37) . One-half milliliter of phenol-red free matrigel (9-11 mg/ml; Biocoat, Becton-Dickinson, San Jose, CA) with 5×10 4 viable MADB106 adenocarcinoma cells was injected s.c. into the flank under fluorethane anesthesia. Seven days later, animals were killed and matrigel implants were collected, weighed, and fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) or immediately frozen in liquid nitrogen and stored at -80 o C.
Experimental metastasis formation
Formation of experimental lung metastasis was determined after injection of 0.5 ml PBS containing 2×10 5 , 4×10 5 or 8×10 5 MADB106 cells into the tail vein under fluorethane anesthesia. After 24 days, animals were killed and lungs were fixed in Bouin's fixative for 24 h. The number of metastasis was determined macroscopically by two independent observers in a blind setup.
Histochemistry
Paraffin-embedded paraformaldehyde (4%) fixed matrigel implants were stained with hematoxylin/eosin for overall histological examination. For vascular endothelial specific cell staining, sections were stained with anti-human factor VIII antibody.
Western blot analysis
Western blot analysis was performed on 50-100 µg total protein from homogenates of matrigel implants in RIPA-buffer (cell lysis buffer containing 10 mM Tris, 5 mM EDTA, and 7.5 mM MgCl 2 ) containing protease inhibitors. Blots were probed with a polyclonal rabbit anti-rat PECAM-1 (CD31) antibody (PharMingen, Becton-Dickinson) and developed using ECL (Amersham, Pharmacia Biotech., Buckinghamshire UK).
Hemoglobin
Hemoglobin contents of matrigel implants were determined in homogenates of frozen implants using the Drabkin reagent kit (Sigma, St Louis, MO).
Statistics
Group differences were evaluated by Student's t test or ANOVA as indicated. P<0.05 was considered statistically significant.
RESULTS
Tumor growth and metastasis formation in APO-SUS and APO-UNSUS animals
To investigate whether the natural differences in dopaminergic reactivity between APO-SUS and APO-UNSUS rats are associated with differences in tumor development, we analyzed tumor growth and metastasis formation. For analysis of tumor growth, rat adenocarcinoma cells (MADB106) in matrigel were implanted s.c. Seven days after implantation of MADB106 cells, tumor weight was determined. As shown in Figure 1 , tumors from APO-SUS rats were significantly smaller that tumors from APO-UNSUS rats.
In a second set of experiments, we analyzed the formation of lung metastases after i.v. administration of MADB106 cells. Twenty-four days after injection of 8×10 5 MADB 106 cells per animal, 78% of the APO-UNSUS died, whereas none of the APO-SUS animals died (Fischer exact test P<0.01). We terminated the experiment at this time point and examined lungs from all animals macroscopically for the presence of metastasis. The number of lung metastases was significantly higher in APO-UNSUS rats (Fig. 2) . Similarly, after i.v. administration of lower numbers of MADB106 cells, the number of tumors in the lung was significantly higher in APO-UNSUS animals than in APO-SUS animals (Fig. 2) .
Tumor angiogenesis in APO-SUS and APO-UNSUS rats
Gross examination of MADB106/matrigel implants suggests that the reduced tumor growth in APO-SUS rats is associated with a reduction in blood supply to the tumor compared to APO-UNSUS rats (Fig. 3A vs. 3B) . Moreover, on histological examination, tumors from APO-SUS rats contained large areas of necrotic cells, whereas tumors in APO-UNSUS rats consist mainly of healthy, dividing tumor cells (Fig. 3C vs. 3D) . Immunohistochemical staining for vascular endothelial cell specific factor VIII expression revealed reduced presence of small vessels in tumors from APO-SUS rats compared with tumors from APO-UNSUS rats (Fig. 3E vs. 3F ). These observations suggest that reduced tumor growth in APO-SUS rats is the result of reduced vascularization of the tumor. Therefore, as a measure of tumor angiogenesis, we determined expression of the endothelial cell marker PECAM-1 in tumor homogenates by Western blot analysis. In line with the macroscopic and histological observations, tumors from APO-SUS rats contain significantly lower levels of PECAM-1 (Fig. 4A) . Moreover, tumors recovered from APO-SUS rats contain less functional capillaries, because hemoglobin content was significantly lower in tumors from APO-SUS than in tumors from APO-UNSUS rats (Fig. 4B) . The lower hemoglobin levels in tumor from APO-SUS rats do not result from differences in hemoglobin level in the peripheral blood (Fig. 4C) .
Angiogenesis in matrigel containing MADB-106-derived growth factors
It is possible that the reduced vascularization of tumors in APO-SUS is caused by the presence of necrotic tumor cells and/or reduced production of growth factors by the tumor in APO-SUS rats. Therefore, we also investigated the angiogenic response in matrigel implants supplemented with MADB106 conditioned medium as a source of tumor-derived growth factors. The conditioned medium used contained 400 pg/ml VEGF. Matrigel containing 30% MADB106 conditioned medium was implanted s.c., and hemoglobin levels were determined 7 days later. Also under these conditions, APO-SUS rats showed a significantly lower level of hemoglobin in the implants, indicating that the decreased angiogenic response in these animals is not secondary to reduced tumor growth factor production or the presence of necrotic cells (Fig. 5) .
Angiogenic response to bFGF-containing corneal implants
To investigate whether the observed differences in angiogenic response represent a general difference in angiogenic capacity between APO-SUS and APO-UNSUS rats, we examined the response to the important angiogenic factor bFGF. Uniformly sized Hydron pellets containing basic fibroblast growth factor (bFGF) were implanted into the cornea adjacent to the temporal limbus. Five days after implantation, neovascularization was examined. We did not observe any difference in angiogenic response to bFGF between APO-SUS and APO-UNSUS rats (APO-SUS: 2.3 ± 0.19 mm 2 , APO-UNSUS: 2.3 ± 0.18 mm 2 ).
DISCUSSION
APO-SUS rats have a hyperreactive dopaminergic system (24, 34) , and dopamine is known to inhibit the growth of malignant tumors as well as VEGF-induced angiogenesis (21) (22) (23) 38) . In addition, APO-SUS rats can be considered as a model for some aspects of schizophrenia (26, 39) , and patients with schizophrenia appear to be protected from cancer (18, 19) . Therefore, we hypothesized that APO-SUS rats will be protected from tumor growth. Our results demonstrate that APO-SUS and APO-UNSUS rats show highly significant differences in angiogenic capacity, tumor growth, and metastasis formation.
Previous studies in different mouse strains have suggested that there are strain-specific differences in the angiogenic capacity of endothelial cells (40) . In those studies, there was a close relationship between the response to bFGF and VEGF of individual animals. However, in this study, we show that APO-SUS rats have a lower angiogenic capacity than APO-UNSUS rats in response to tumor cells or tumor cell conditioned medium containing high amounts of VEGF. In contrast, the angiogenic response to bFGF is similar in both types of animals. These data suggest that the difference in angiogenic response between APO-SUS and APO-UNSUS rats is not dependent on the overall capacity of endothelial cells to form novel capillaries but is linked to specific differences in the response to specific growth factors other than bFGF.
As already mentioned, the selection criterium for breeding the two lines of Wistar rat was the behavioral response to the dopaminergic receptor agonist apomorphine: APO-SUS rats have a far greater response to apomorphine than APO-UNSUS rats (24, 25) . In addition, APO-SUS rats have increased levels of mRNA of tyrosine-hydroxylase in dopaminergic cells in the midbrain, especially the substantia nigra pars compacta. Furthermore they have increased expression of mRNA encoding D1 dopamine receptors in the neostriatum, increased numbers of dopamine D2 receptors in the neostriatum, and increased stress-induced dopamine release from the nucleus accumbens (34) . Interestingly, previous studies have shown that administration of a dopaminergic agonist can inhibit tumor growth (21, 22) . In addition, the angiogenic response to VEGF but not to bFGF can be inhibited by administration of dopaminergic agonists (21) . Moreover, dopaminergic agonists inhibit signaling through the VEGF receptor (21) . Thus, it may well be possible that increased plasma dopamine levels and/or dopamine content in peripheral nerve terminals adjacent to blood vessels and/or increased reactivity of endothelial dopamine receptors are responsible for the observed lower angiogenic response in APO-SUS rats.
Future studies are required to assess whether it is a line-specific difference in the dopaminergic activity in the peripheral nervous system rather than in the central nervous system that underlies the observed differences in tumor growth and angiogenesis between APO-SUS and APO-UNSUS rats. There is evidence, however, that central dopaminergic activity directly and/or indirectly controls peripheral processes that are under control of peripheral dopamine as well. For example, administration of dopamine can control gastric ulceration via an effect on both central as well as peripheral dopamine receptors. Moreover, apomorphine-susceptibility is negatively correlated with gastric ulceration (41) . Finally, it has been shown that depletion of central dopamine by treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in enhanced growth of a s.c.-implanted Erhlich carcinoma in a murine model (38) . These data clearly suggest that central dopaminergic activity has consequences for processes that are under the control of peripheral dopamine as well.
It is important to realize, however, that the differences between APO-SUS and APO-UNSUS rats are not limited to the dopaminergic system but also extend to other systems that interact with the dopaminergic system. For example, APO-SUS rats show a large and long-lasting endocrine response to stressors in terms of release of ACTH and corticosteroids, whereas APO-UNSUS rats show small and short-lasting endocrine responses to stress (32) .
In line with the differences in the HPA-axis, APO-SUS and APO-UNSUS rats differ in development of periodontitis, in susceptibility to autoimmune diseases, and to parasite infection (42, 43) . In the immune system, the lower susceptibility of APO-SUS rats to autoimmune diseases and their increased IgE production after parasitic infection correlates with a relative increase in production of Th-2 type cytokines (43) . Interestingly, there is evidence that high doses of the Th2 cytokine interleukin-4 can inhibit angiogenesis (44) . Moreover, transgenic interleukin-4 producing tumors can inhibit growth and angiogenesis in contralaterally implanted tumors that do not produce the cytokine (45) . However, at lower concentrations IL-4 has the capacity to induce angiogenesis (46) . Although we do not have evidence for infiltration of immune cells in the MADB106 tumors, it is possible that the Th2-dominated immune system of APO-SUS rats contributes to the reduced tumor growth and angiogenesis in these animals.
Angiogenesis is not only essential for the growth of solid tumors but also plays a major role in wound healing (3, 47) . Our present data suggest that individual differences in dopaminergic reactivity may also contribute significantly to the rate of wound healing. Indeed, we have recently found that the healing of gastric ulcers in APO-SUS rats is significantly slower than that in APO-UNSUS rats (Degen, S.B.; Geven, E.J.W.; Sluyter, F.; Hof, M.; van der Elst, M.C.J. and Cools, A.R., unpublished observations). In addition, there is evidence that dopamine can also modulate normal physiological vessel formation. For example, D2-dopaminergic receptors have been identified on vascular endothelial cells in the human placenta and the D2-agonist apomorphine inhibits neovascularization in a chick-chorioallantoic membrane assay (CAM) (48) .
As mentioned in the introduction, APO-SUS rats share several characteristics with patients who suffer from schizophrenia (24, (26) (27) (28) (29) (30) (31) 39) , and there are studies showing that the incidence of cancer is reduced in these patients (18, 19) . The reduced angiogenic response and the associated reduction in tumor growth or metastasis formation in APO-SUS rats suggest that the APO-SUS rat is a valuable tool in the search for the contribution of genetic and environmental stimuli to the apparent protection of patients with schizophrenia from cancer.
Overall, our results suggest a novel link between hyperreactivity of the dopaminergic system, angiogenesis, and tumor development and may explain part of the host-dependent individual differences in cancer progression. It would be interesting to investigate whether the reactivity of the dopaminergic system in humans diagnosed with cancer can be used as a tool to select patients for antiangiogenic therapy. , n=6) and APO-UNSUS rats (closed bars, n=8). On day 7 after implantation, rats were killed. Tumors were collected, and wet weight was determined. ** P<0.01. 30% MADB-106 conditioned medium was implanted s.c., and 7 days later, hemoglobin levels were determined. Open bars: APO-SUS rats, n=8. Closed bars: APO-UNSUS rats, n=8. *P<0.05.
